Trial Profile
HIGH-DOSE SEQUENTIAL CHEMOTHERAPY AND RITUXIMAB (R-HDS) IN HIV+ PATIENTS WITH NON-HODGKIN LYMPHOMA (NHL) REFRACTORY OR RELAPSED AFTER 1st LINE TREATMENT.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Cyclophosphamide (Primary) ; Cytarabine (Primary) ; Dexamethasone (Primary) ; Etoposide (Primary) ; Filgrastim (Primary) ; Melphalan (Primary) ; Mitoxantrone (Primary) ; Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Primary-Effusion-Lymphoma
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2013 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 18 Aug 2011 New trial record